The obstetric syndromes: clinical relevance of placental hormones

References

• De Bonis M, Torricelli M, Severi FM, Luisi S, De Leo V, Petraglia F. Neuroendocrine aspects of placenta and pregnancy. Gynecol. Endocrinol. 28(Suppl. 1), 22–26 (2012).
   PubMed Web of Science ®Google Scholar
• Feldt-Rasmussen U, Mathiesen ER. Endocrine disorders in pregnancy: physiological and hormonal aspects of pregnancy. Best Pract. Res. Clin. Endocrinol. Metab. 25(6), 875–884 (2011).
   PubMed Web of Science ®Google Scholar
• Cetin I, Huppertz B, Burton G et al. Pregenesys preeclampsia markers consensus meeting: what do we require from markers, risk assessment and model systems to tailor preventive strategies? Placenta 32(Suppl.), S4–S16 (2011).
   PubMed Web of Science ®Google Scholar
• American College of Obstetrician and Gynecologists. Intrauterine growth restriction. ACOG Practice Bulletin N. 12 (2000).
   Google Scholar
• Romero R, Espinoza J, Kusanovic JP et al. The preterm parturition syndrome. BJOG 113(Suppl. 3), 17–42 (2006).
   PubMed Web of Science ®Google Scholar
• Brosens I, Pijnenborg R, Vercruysse L, Romero R. The ‘Great Obstetrical Syndromes’ are associated with disorders of deep placentation. Am. J. Obstet. Gynecol. 204(3), 193–201 (2011).
   PubMed Web of Science ®Google Scholar
• Romero R, Kusanovic JP, Chaiworapongsa T, Hassan SS. Placental bed disorders in preterm labor, preterm PROM, spontaneous abortion and abruptio placentae. Best Pract. Res. Clin. Obstet. Gynaecol. 25(3), 313–327 (2011).
   PubMed Web of Science ®Google Scholar
• Khong Y, Brosens I. Defective deep placentation. Best Pract. Res. Clin. Obstet. Gynaecol. 25(3), 301–311 (2011).
   PubMed Web of Science ®Google Scholar
• Pijnenborg R, Vercruysse L, Brosens I. Deep placentation. Best Pract. Res. Clin. Obstet. Gynaecol. 25(3), 273–285 (2011).
   PubMed Web of Science ®Google Scholar
• Kim YM, Chaiworapongsa T, Gomez R et al. Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. Am. J. Obstet. Gynecol. 187(5), 1137–1142 (2002).
   PubMed Web of Science ®Google Scholar
• Reis FM, D’Antona D, Petraglia F. Predictive value of hormone measurements in maternal and fetal complications of pregnancy. Endocr. Rev. 23(2), 230–257 (2002).
   PubMed Web of Science ®Google Scholar
• Murphy VE, Smith R, Giles WB, Clifton VL. Endocrine regulation of human fetal growth: the role of the mother, placenta, and fetus. Endocr. Rev. 27(2), 141–169 (2006).
   PubMed Web of Science ®Google Scholar
• Torricelli M, Voltolini C, De Bonis M et al. The identification of high risk pregnancy: a new challenge in obstetrics. J. Matern. Fetal. Neonatal. Med. 25(Suppl. 1), 2–5 (2012).
   PubMed Web of Science ®Google Scholar
• Brosens JJ, Pijnenborg R, Brosens IA. The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature. Am. J. Obstet. Gynecol. 187(5), 1416–1423 (2002).
   PubMed Web of Science ®Google Scholar
• Hering L, Herse F, Verlohren S et al. Trophoblasts reduce the vascular smooth muscle cell proatherogenic response. Hypertension 51(2), 554–559 (2008).
   PubMed Web of Science ®Google Scholar
• Haller H, Hempel A, Homuth V et al. Endothelial-cell permeability and protein kinase C in preeclampsia. Lancet 351(9107), 945–949 (1998).
   PubMed Web of Science ®Google Scholar
• Wang Y, Lewis DF, Alexander JS, Granger DN. Endothelial barrier function in preeclampsia. Front. Biosci. 12, 2412–2424 (2007).
   PubMed Web of Science ®Google Scholar
• Perry KG Jr, Martin JN Jr. Abnormal hemostasis and coagulopathy in preeclampsia and eclampsia. Clin. Obstet. Gynecol. 35(2), 338–350 (1992).
   PubMed Web of Science ®Google Scholar
• Haller H, Ziegler EM, Homuth V et al. Endothelial adhesion molecules and leukocyte integrins in preeclamptic patients. Hypertension 29(1 Pt 2), 291–296 (1997).
   PubMed Web of Science ®Google Scholar
• Kalinderis M, Papanikolaou A, Kalinderi K et al. Elevated serum levels of interleukin-6, interleukin-1β and human chorionic gonadotropin in preeclampsia. Am. J. Reprod. Immunol. 66(6), 468–475 (2011).
   PubMed Web of Science ®Google Scholar
• Bahado-Singh RO, Oz U, Isozaki T et al. Midtrimester urine human chorionic gonadotropin β-subunit core fragment levels and the subsequent development of preeclampsia. Am. J. Obstet. Gynecol. 179(3 Pt 1), 738–741 (1998).
   PubMed Web of Science ®Google Scholar
• Dugoff L, Hobbins JC, Malone FD et al. First-trimester maternal serum PAPP-A and free-β subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am. J. Obstet. Gynecol. 191(4), 1446–1451 (2004).
   PubMed Web of Science ®Google Scholar
• Odibo AO, Zhong Y, Goetzinger KR et al. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of preeclampsia. Placenta 32(8), 598–602 (2011).
   PubMed Web of Science ®Google Scholar
• Spencer K, Cowans NJ, Nicolaides KH. Low levels of maternal serum PAPP-A in the first trimester and the risk of preeclampsia. Prenat. Diagn. 28(1), 7–10 (2008).
   PubMed Web of Science ®Google Scholar
• Nicolaides KH, Bindra R, Turan OM et al. A novel approach to first-trimester screening for early preeclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet. Gynecol. 27(1), 13–17 (2006).
   PubMed Web of Science ®Google Scholar
• Romero R, Kusanovic JP, Than NG et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am. J. Obstet. Gynecol. 199(2), 122.e1–122.e11 (2008).
   Web of Science ®Google Scholar
• Florio P, Torricelli M, De Falco G et al. High maternal and fetal plasma urocortin levels in pregnancies complicated by hypertension. J. Hypertens. 24(9), 1831–1840 (2006).
   PubMed Web of Science ®Google Scholar
• Giles WB, McLean M, Davies JJ, Smith R. Abnormal umbilical artery Doppler waveforms and cord blood corticotropin-releasing hormone. Obstet. Gynecol. 87(1), 107–111 (1996).
   PubMed Web of Science ®Google Scholar
• Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and angiogenic imbalance. Annu. Rev. Med. 59, 61–78 (2008).
   PubMed Web of Science ®Google Scholar
• Florio P, Ciarmela P, Luisi S et al. Preeclampsia with fetal growth restriction: placental and serum activin A and inhibin A levels. Gynecol. Endocrinol. 16(5), 365–372 (2002).
   PubMed Web of Science ®Google Scholar
• Ree PH, Hahn WB, Chang SW et al. Early detection of preeclampsia using inhibin a and other second-trimester serum markers. Fetal. Diagn. Ther. 29(4), 280–286 (2011).
   PubMed Web of Science ®Google Scholar
• Akolekar R, Minekawa R, Veduta A, Romero XC, Nicolaides KH. Maternal plasma inhibin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Prenat. Diagn. 29, 753–760 (2009).
   PubMed Web of Science ®Google Scholar
• Muttukrishna S, North RA, Morris J et al. Serum inhibin A and activin A are elevated prior to the onset of preeclampsia. Hum. Reprod. 15(7), 1640–1645 (2000).
   PubMed Web of Science ®Google Scholar
• Spencer K, Yu CK, Savvidou M, Papageorghiou AT, Nicolaides KH. Prediction of preeclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free β-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks’ gestation. Ultrasound Obstet. Gynecol. 27(6), 658–663 (2006).
   PubMed Web of Science ®Google Scholar
• Florio P, Reis FM, Pezzani I, Luisi S, Severi FM, Petraglia F. The addition of activin A and inhibin A measurement to uterine artery Doppler velocimetry to improve the early prediction of preeclampsia. Ultrasound Obstet. Gynecol. 21(2), 165–169 (2003).
   PubMed Web of Science ®Google Scholar
• Andraweera PH, Dekker GA, Laurence JA, Roberts CT. Placental expression of VEGF family mRNA in adverse pregnancy outcomes. Placenta 33(6), 467–472 (2012).
   PubMed Web of Science ®Google Scholar
• Cooper JC, Sharkey AM, Charnock-Jones DS, Palmer CR, Smith SK. VEGF mRNA levels in placentae from pregnancies complicated by preeclampsia. Br. J. Obstet. Gynaecol. 103(12), 1191–1196 (1996).
   PubMedGoogle Scholar
• Smith GC, Crossley JA, Aitken DA et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet. Gynecol. 109(6), 1316–1324 (2007).
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350(7), 672–683 (2004).
   PubMed Web of Science ®Google Scholar
• Lacroix MC, Guibourdenche J, Fournier T et al. Stimulation of human trophoblast invasion by placental growth hormone. Endocrinology 146(5), 2434–2444 (2005).
   PubMed Web of Science ®Google Scholar
• Vandenberghe G, Mensink I, Twisk JW, Blankenstein MA, Heijboer AC, van Vugt JM. First trimester screening for intra-uterine growth restriction and early-onset preeclampsia. Prenat. Diagn. 31(10), 955–961 (2011).
   PubMed Web of Science ®Google Scholar
• Verlohren S, Herraiz I, Lapaire O et al. Risk stratification of hypertensive pregnancy disorders. Eur. Ob. Gyn. 7, 14–17 (2012).
   Google Scholar
• Verlohren S, Herraiz I, Lapaire O et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am. J. Obstet. Gynecol. 206(1), 58.e1–58.e8 (2012).
   PubMed Web of Science ®Google Scholar
• Molvarec A, Szarka A, Walentin S, Szucs E, Nagy B, Rigó J Jr. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with preeclampsia. Hypertens. Res. 33(9), 892–898 (2010).
   PubMed Web of Science ®Google Scholar
• Ning Y, Williams MA, Muy-Rivera M, Leisenring WM, Luthy DA. Relationship of maternal plasma leptin and risk of preeclampsia: a prospective study. J. Matern. Fetal. Neonatal. Med. 15(3), 186–192 (2004).
   PubMedGoogle Scholar
• Miehle K, Stepan H, Fasshauer M. Leptin, adiponectin and other adipokines in gestational diabetes mellitus and pre-eclampsia. Clin. Endocrinol. (Oxf.) 76(1), 2–11 (2012).
   PubMed Web of Science ®Google Scholar
• Tan KC, Xu A, Chow WS et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J. Clin. Endocrinol. Metab. 89(2), 765–769 (2004).
   PubMed Web of Science ®Google Scholar
• D’Anna R, Baviera G, Corrado F, Giordano D, Di Benedetto A, Jasonni VM. Plasma adiponectin concentration in early pregnancy and subsequent risk of hypertensive disorders. Obstet. Gynecol. 106(2), 340–344 (2005).
   PubMed Web of Science ®Google Scholar
• Dalamaga M, Srinivas SK, Elovitz MA, Chamberland J, Mantzoros CS. Serum adiponectin and leptin in relation to risk for preeclampsia: results from a large case-control study. Metab. Clin. Exp. 60(11), 1539–1544 (2011).
   PubMed Web of Science ®Google Scholar
• Grill S, Rusterholz C, Zanetti-Dällenbach R et al. Potential markers of preeclampsia – a review. Reprod. Biol. Endocrinol. 7, 70 (2009).
   PubMed Web of Science ®Google Scholar
• Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. J. Thromb. Haemost. 3(8), 1590–1596 (2005).
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Yoshimatsu J et al. Soluble adhesion molecule profile in normal pregnancy and preeclampsia. J. Matern. Fetal. Neonatal. Med. 12(1), 19–27 (2002).
   PubMedGoogle Scholar
• Banzola I, Farina A, Concu M et al. Performance of a panel of maternal serum markers in predicting preeclampsia at 11–15 weeks’ gestation. Prenat. Diagn. 27(11), 1005–1010 (2007).
   PubMed Web of Science ®Google Scholar
• Shaker OG, Shehata H. Early prediction of preeclampsia in high-risk women. J. Womens. Health (Larchmt.) 20(4), 539–544 (2011).
   PubMed Web of Science ®Google Scholar
• Rusterholz C, Hahn S, Holzgreve W. Role of placentally produced inflammatory and regulatory cytokines in pregnancy and the etiology of preeclampsia. Semin. Immunopathol. 29(2), 151–162 (2007).
   PubMed Web of Science ®Google Scholar
• Derzsy Z, Prohászka Z, Rigó J Jr, Füst G, Molvarec A. Activation of the complement system in normal pregnancy and preeclampsia. Mol. Immunol. 47(7–8), 1500–1506 (2010).
   PubMed Web of Science ®Google Scholar
• Molvarec A, Szarka A, Walentin S et al. Serum heat shock protein 70 levels in relation to circulating cytokines, chemokines, adhesion molecules and angiogenic factors in women with preeclampsia. Clin. Chim. Acta 412(21–22), 1957–1962 (2011).
   PubMed Web of Science ®Google Scholar
• Szarka A, Rigó J Jr, Lázár L, Beko G, Molvarec A. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol. 11, 59 (2010).
   PubMed Web of Science ®Google Scholar
• Lynch AM, Murphy JR, Byers T et al. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am. J. Obstet. Gynecol. 198, 385.e1–e9 (2008).
   Web of Science ®Google Scholar
• Lynch AM, Gibbs RS, Murphy JR, Giclas PC, Salmon JE, Holers VM. Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet. Gynecol. 117(1), 75–83 (2011).
   PubMed Web of Science ®Google Scholar
• Bahado-Singh RO, Akolekar R, Mandal R et al. Metabolomics and first-trimester prediction of early-onset preeclampsia. J. Matern. Fetal. Neonatal. Med. 25(10), 1840–1847 (2012).
   PubMed Web of Science ®Google Scholar
• Kenny LC, Broadhurst DI, Dunn W et al.; Screening for Pregnancy Endpoints Consortium. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension 56(4), 741–749 (2010).
   PubMed Web of Science ®Google Scholar
• Giles WB, Trudinger BJ, Baird PJ. Fetal umbilical artery flow velocity waveforms and placental resistance: pathological correlation. Br. J. Obstet. Gynaecol. 92(1), 31–38 (1985).
   PubMedGoogle Scholar
• Krebs C, Macara LM, Leiser R, Bowman AW, Greer IA, Kingdom JC. Intrauterine growth restriction with absent end-diastolic flow velocity in the umbilical artery is associated with maldevelopment of the placental terminal villous tree. Am. J. Obstet. Gynecol. 175(6), 1534–1542 (1996).
   PubMed Web of Science ®Google Scholar
• Macara L, Kingdom JC, Kaufmann P et al. Structural analysis of placental terminal villi from growth-restricted pregnancies with abnormal umbilical artery Doppler waveforms. Placenta 17(1), 37–48 (1996).
   PubMed Web of Science ®Google Scholar
• Salafia CM. Placental pathology of fetal growth restriction. Clin. Obstet. Gynecol. 40(4), 740–749 (1997).
   PubMed Web of Science ®Google Scholar
• Regnault TRH, Galanb HL, Parkera TA et al. Placental development in IUGR pregnancies. Placenta 23, 119–129 (2002).
   PubMed Web of Science ®Google Scholar
• Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe preeclamptic pregnancies. Br. J. Obstet. Gynaecol. 101(8), 669–674 (1994).
   PubMedGoogle Scholar
• Redline RW, Patterson P. Preeclampsia is associated with an excess of proliferative immature intermediate trophoblast. Hum. Pathol. 26(6), 594–600 (1995).
   PubMed Web of Science ®Google Scholar
• Robertson WB, Brosens I, Dixon G. Uteroplacental vascular pathology. Eur. J. Obstet. Gynecol. Reprod. Biol. 5(1–2), 47–65 (1975).
   PubMedGoogle Scholar
• Gardosi J, Mongelli M, Wilcox M, Chang A. An adjustable fetal weight standard. Ultrasound Obstet. Gynecol. 6(3), 168–174 (1995).
   PubMed Web of Science ®Google Scholar
• Ferrazzi E, Bulfamante G, Mezzopane R, Barbera A, Ghidini A, Pardi G. Uterine Doppler velocimetry and placental hypoxic-ischemic lesion in pregnancies with fetal intrauterine growth restriction. Placenta 20(5-6), 389–394 (1999).
   PubMed Web of Science ®Google Scholar
• Wallner W, Sengenberger R, Strick R et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin. Sci. 112(1), 51–57 (2007).
   PubMed Web of Science ®Google Scholar
• Ahmed A, Dunk C, Ahmad S, Khaliq A. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen – a review. Placenta 21(Suppl. A), S16–S24 (2000).
   PubMed Web of Science ®Google Scholar
• Nevo O, Many A, Xu J et al. Placental expression of soluble fms-like tyrosine kinase 1 is increased in singletons and twin pregnancies with intrauterine growth restriction. J. Clin. Endocrinol. Metab. 93(1), 285–292 (2008).
   PubMed Web of Science ®Google Scholar
• Ong CY, Liao AW, Spencer K, Munim S, Nicolaides KH. First trimester maternal serum free β human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 107(10), 1265–1270 (2000).
   PubMed Web of Science ®Google Scholar
• Kirkegaard I, Henriksen TB, Uldbjerg N. Early fetal growth, PAPP-A and free β-hCG in relation to risk of delivering a small-for-gestational age infant. Ultrasound Obstet. Gynecol. 37(3), 341–347 (2011).
   PubMed Web of Science ®Google Scholar
• Spencer K. Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome. Prenat. Diagn. 20(8), 652–656 (2000).
   PubMed Web of Science ®Google Scholar
• Gardner MO, Goldenberg RL, Cliver SP, Boots LR, Hoffman HJ. Maternal serum concentrations of human placental lactogen, estradiol and pregnancy specific β 1-glycoprotein and fetal growth retardation. Acta Obstet. Gynecol. Scand. Suppl. 165, 56–58 (1997).
   PubMedGoogle Scholar
• Bersinger NA, Ødegård RA. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet. Gynecol. Scand. 83(1), 37–45 (2004).
   PubMed Web of Science ®Google Scholar
• Holcom WL Jr, Smeltzer JS. Cervical effacement: variation in belief among clinicians. Obstet. Gynecol. 78, 43–45 (1991).
   PubMed Web of Science ®Google Scholar
• Sonek JD, Iams JD, Blumenfeld M, Johnson F, Landon M, Gabbe S. Measurement of cervical length in pregnancy: comparison between vaginal ultrasonography and digital examination. Obstet. Gynecol. 76(2), 172–175 (1990).
   PubMed Web of Science ®Google Scholar
• Mella MT, Berghella V. Prediction of preterm birth: cervical sonography. Semin. Perinatol. 33(5), 317–324 (2009).
   PubMed Web of Science ®Google Scholar
• Honest H, Forbes CA, Durée KH et al. Screening to prevent spontaneous preterm birth: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol. Assess. 13(43), 1–627 (2009).
   PubMed Web of Science ®Google Scholar
• Berghella V, Hayes E, Visintine J, Baxter JK. Fetal fibronectin testing for reducing the risk of preterm birth. Cochrane Database Syst. Rev. 4, CD006843 (2008).
   PubMed Web of Science ®Google Scholar
• Goodwin TM. A role for estriol in human labor, term and preterm. Am. J. Obstet. Gynecol. 180(1 Pt 3), S208–S213 (1999).
   PubMed Web of Science ®Google Scholar
• McGregor JA, Jackson GM, Lachelin GC et al. Salivary estriol as risk assessment for preterm labor: a prospective trial. Am. J. Obstet. Gynecol. 173(4), 1337–1342 (1995).
   PubMed Web of Science ®Google Scholar
• Heine RP, McGregor JA, Goodwin TM et al. Serial salivary estriol to detect an increased risk of preterm birth. Obstet. Gynecol. 96(4), 490–497 (2000).
   PubMed Web of Science ®Google Scholar
• Smith R, Smith JI, Shen X et al. Patterns of plasma corticotropin-releasing hormone, progesterone, estradiol, and estriol change and the onset of human labor. J. Clin. Endocrinol. Metab. 94(6), 2066–2074 (2009).
   PubMed Web of Science ®Google Scholar
• Lockwood CJ. The diagnosis of preterm labor and the prediction of preterm delivery. Clin. Obstet. Gynecol. 38(4), 675–687 (1995).
   PubMed Web of Science ®Google Scholar
• Petraglia F, Aguzzoli L, Florio P et al. Maternal plasma and placental immunoreactive corticotrophin-releasing factor concentrations in infection-associated term and pre-term delivery. Placenta 16(2), 157–164 (1995).
   PubMed Web of Science ®Google Scholar
• Hobel CJ, Dunkel-Schetter C, Roesch SC, Castro LC, Arora CP. Maternal plasma corticotropin-releasing hormone associated with stress at 20 weeks’ gestation in pregnancies ending in preterm delivery. Am. J. Obstet. Gynecol. 180(1 Pt 3), S257–S263 (1999).
   PubMed Web of Science ®Google Scholar
• McLean M, Bisits A, Davies J et al. Predicting risk of preterm delivery by second-trimester measurement of maternal plasma corticotropin-releasing hormone and α-fetoprotein concentrations. Am. J. Obstet. Gynecol. 181(1), 207–215 (1999).
   PubMed Web of Science ®Google Scholar
• Florio P, Linton EA, Torricelli M et al. Prediction of preterm delivery based on maternal plasma urocortin. J. Clin. Endocrinol. Metab. 92(12), 4734–4737 (2007).
   PubMed Web of Science ®Google Scholar
• Petraglia F, Imperatore A, Challis JR. Neuroendocrine mechanisms in pregnancy and parturition. Endocr. Rev. 31(6), 783–816 (2010).
   PubMed Web of Science ®Google Scholar
• Spencer K, Cowans NJ, Molina F, Kagan KO, Nicolaides KH. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery. Ultrasound Obstet. Gynecol. 31(2), 147–152 (2008).
   PubMed Web of Science ®Google Scholar
• Lieppman RE, Williams MA, Cheng EY et al. An association between elevated levels of human chorionic gonadotropin in the midtrimester and adverse pregnancy outcome. Am. J. Obstet. Gynecol. 168(6 Pt 1), 1852–1856; discussion 1856 (1993).
   PubMed Web of Science ®Google Scholar
• Jelliffe-Pawlowski LL, Baer RJ, Currier RJ. Second trimester serum predictors of preterm birth in a population-based sample of low-risk pregnancies. Prenat. Diagn. 30(8), 727–733 (2010).
   PubMed Web of Science ®Google Scholar
• Bernstein PS, Stern R, Lin N et al. β-human chorionic gonadotropin in cervicovaginal secretions as a predictor of preterm delivery. Am. J. Obstet. Gynecol. 179(4), 870–873 (1998).
   PubMed Web of Science ®Google Scholar
• Cruciani L, Romero R, Vaisbuch E et al. Pentraxin 3 in maternal circulation: an association with preterm labor and preterm PROM, but not with intra-amniotic infection/inflammation. J. Matern. Fetal. Neonatal. Med. 23(10), 1097–1105 (2010).
   PubMed Web of Science ®Google Scholar
• Cooper S, Lange I, Wood S, Tang S, Miller L, Ross S. Diagnostic accuracy of rapid phIGFBP-I assay for predicting preterm labor in symptomatic patients. J. Perinatol. 32(6), 460–465 (2012).
   PubMed Web of Science ®Google Scholar
• Danti L, Prefumo F, Lojacono A, Corini S, Testori A, Frusca T. The combination of short cervical length and phIGFBP-1 in the prediction of preterm delivery in symptomatic women. J. Matern. Fetal. Neonatal. Med. 24(10), 1262–1266 (2011).
   PubMed Web of Science ®Google Scholar
• Demendi C, Börzsönyi B, Nagy ZB, Rigó J Jr, Pajor A, Joó JG. Gene expression patterns of insulin-like growth factor 1, 2 (IGF-1, IGF-2) and insulin-like growth factor binding protein 3 (IGFBP-3) in human placenta from preterm deliveries: influence of additional factors. Eur. J. Obstet. Gynecol. Reprod. Biol. 160(1), 40–44 (2012).
   PubMed Web of Science ®Google Scholar
• Conde-Agudelo A, Papageorghiou AT, Kennedy SH, Villar J. Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis. BJOG 118(9), 1042–1054 (2011).
   PubMed Web of Science ®Google Scholar
• Goldenberg RL, Iams JD, Mercer BM et al.; Maternal-Fetal Medicine Units Network. The Preterm Prediction Study: toward a multiple-marker test for spontaneous preterm birth. Am. J. Obstet. Gynecol. 185(3), 643–651 (2001).
   PubMed Web of Science ®Google Scholar
• Coleman MA, Keelan JA, McCowan LM, Townend KM, Mitchell MD. Predicting preterm delivery: comparison of cervicovaginal interleukin (IL)-1β, IL-6 and IL-8 with fetal fibronectin and cervical dilatation. Eur. J. Obstet. Gynecol. Reprod. Biol. 95(2), 154–158 (2001).
   PubMed Web of Science ®Google Scholar
• Gervasi MT, Romero R, Bracalente G et al. Midtrimester amniotic fluid concentrations of interleukin-6 and interferon-γ-inducible protein-10: evidence for heterogeneity of intra-amniotic inflammation and associations with spontaneous early (<32 weeks) and late (>32 weeks) preterm delivery. J. Perinat. Med. 40(4), 329–343 (2012).
   PubMed Web of Science ®Google Scholar
• Norwitz ER, Caughey AB. Progesterone supplementation and the prevention of preterm birth. Rev. Obstet. Gynecol. 4(2), 60–72 (2011).
   PubMedGoogle Scholar
• Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am. J. Obstet. Gynecol. 206, 376–386 (2012).
   PubMed Web of Science ®Google Scholar
• Waffarn F, Davis EP. Effects of antenatal corticosteroids on the hypothalamic-pituitary-adrenocortical axis of the fetus and newborn: experimental findings and clinical considerations. Am. J. Obstet. Gynecol. 207(6), 446–454 (2012).
   PubMed Web of Science ®Google Scholar
• Berkman ND, Thorp JM Jr, Hartmann KE et al. Management of preterm labor. Evidence Report/Technology Assessment No. 18 (Prepared by Research Triangle Institute under Contract No. 290-97-0011). AHRQ Publication No. 01-E021. Agency for Healthcare Research and Quality (Level III), Rockville, MD, USA (2000).
   Google Scholar
• Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst. Rev. 18, CD000065 (2007).
   Google Scholar
• Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst. Rev. 3, CD004454 (2006).
   PubMed Web of Science ®Google Scholar
• Kapoor A, Dunn E, Kostaki A, Andrews MH, Matthews SG. Fetal programming of hypothalamo–pituitary–adrenal function: prenatal stress and glucocorticoids. J. Physiol. (Lond.) 572(Pt 1), 31–44 (2006).
   Google Scholar